Stock Track | Progyny Soars 22.08% in Intraday Trading on Strong Q1 Earnings Beat, Raised Guidance and Analyst Upgrade

Stock Track

Yesterday

Progyny's stock surged 22.08% during intraday trading on Friday, marking a significant upward movement for the women's health benefits provider.

The sharp rise follows the company's release of first-quarter 2026 financial results that substantially exceeded analyst expectations. Progyny reported adjusted earnings per share of $0.50, beating consensus estimates of $0.30 by 66.67%, while revenue of $328.5 million also came in above expectations. The company's net income saw a substantial 60.9% year-over-year increase to $24.2 million, with gross margin expanding to 25.3%.

Adding to the positive momentum, Progyny raised its full-year adjusted EPS outlook to a range of $1.98 to $2.09, up from previous guidance. Furthermore, Bofa Global Research raised its price objective on Progyny to $29.00 from $27.00, reflecting increased analyst confidence in the company's growth prospects despite macroeconomic uncertainty.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1118272526"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1118272526\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1118272526?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 21:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118272526","market":"nz","top_or_hot":-1,"title":"Stock Track | Progyny Soars 22.08% in Intraday Trading on Strong Q1 Earnings Beat, Raised Guidance and Analyst Upgrade","media":"Stock Track","content":"<p>Progyny's stock surged 22.08% during intraday trading on Friday, marking a significant upward movement for the women's health benefits provider.</p><p>The sharp rise follows the company's release of first-quarter 2026 financial results that substantially exceeded analyst expectations. Progyny reported adjusted earnings per share of $0.50, beating consensus estimates of $0.30 by 66.67%, while revenue of $328.5 million also came in above expectations. The company's net income saw a substantial 60.9% year-over-year increase to $24.2 million, with gross margin expanding to 25.3%.</p><p>Adding to the positive momentum, Progyny raised its full-year adjusted EPS outlook to a range of $1.98 to $2.09, up from previous guidance. Furthermore, Bofa Global Research raised its price objective on Progyny to $29.00 from $27.00, reflecting increased analyst confidence in the company's growth prospects despite macroeconomic uncertainty.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Progyny Soars 22.08% in Intraday Trading on Strong Q1 Earnings Beat, Raised Guidance and Analyst Upgrade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Progyny Soars 22.08% in Intraday Trading on Strong Q1 Earnings Beat, Raised Guidance and Analyst Upgrade\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-08 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Progyny's stock surged 22.08% during intraday trading on Friday, marking a significant upward movement for the women's health benefits provider.</p><p>The sharp rise follows the company's release of first-quarter 2026 financial results that substantially exceeded analyst expectations. Progyny reported adjusted earnings per share of $0.50, beating consensus estimates of $0.30 by 66.67%, while revenue of $328.5 million also came in above expectations. The company's net income saw a substantial 60.9% year-over-year increase to $24.2 million, with gross margin expanding to 25.3%.</p><p>Adding to the positive momentum, Progyny raised its full-year adjusted EPS outlook to a range of $1.98 to $2.09, up from previous guidance. Furthermore, Bofa Global Research raised its price objective on Progyny to $29.00 from $27.00, reflecting increased analyst confidence in the company's growth prospects despite macroeconomic uncertainty.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PGNY","symbol_name":"Progyny","start_time":0,"source_url":"","article_id":"1118272526","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118272526","pubTimestamp":1778247787,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Progyny's stock surged 22.08% during intraday trading on Friday, marking a significant upward movement for the women's health benefits provider.The sharp rise follows the company's release of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PGNY":"Progyny"},"translate_title":"个股追踪|Progyny盘中飙升22.08%，因Q1盈利强劲、指引上调和分析师升级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PGNY":1},"content_text":"Progyny's stock surged 22.08% during intraday trading on Friday, marking a significant upward movement for the women's health benefits provider.The sharp rise follows the company's release of first-quarter 2026 financial results that substantially exceeded analyst expectations. Progyny reported adjusted earnings per share of $0.50, beating consensus estimates of $0.30 by 66.67%, while revenue of $328.5 million also came in above expectations. The company's net income saw a substantial 60.9% year-over-year increase to $24.2 million, with gross margin expanding to 25.3%.Adding to the positive momentum, Progyny raised its full-year adjusted EPS outlook to a range of $1.98 to $2.09, up from previous guidance. Furthermore, Bofa Global Research raised its price objective on Progyny to $29.00 from $27.00, reflecting increased analyst confidence in the company's growth prospects despite macroeconomic uncertainty.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}